Fan Xin-Tong, Gao Bing-Fang, Wang Xiao-Fei, Zhou Kai, Zhao Ying, Yuan Jie
TCM-Integrated Hospital of Zibo, Zibo, China.
J Mol Recognit. 2024 Mar;37(2):e3071. doi: 10.1002/jmr.3071. Epub 2024 Jan 2.
Cancer is associated with the highest mortality rate globally. While life-saving screening and treatments exist, better awareness is needed. RNF187, an E3 ligase regulating biological processes, belongs to the RING domain-containing E3 ligase family. RNF187 may serve as an oncogene due to abnormal expression in tumors. However, its association with immune infiltration and prognosis across various cancers remains unclear. We searched several databases including TCGA, GTE x, CCLE, TIMER, and GSEA. R software was used to evaluate RNF187 differential expression, survival, pathology stage, DNA methylation, tumor mutational burden (TMB), microsatellite instability (MSI), gene co-expression analysis, mismatch repairs (MMRs), tumor microenvironment (TME), and immune cell infiltration. Clinicopathological data were collected, and immunohistochemistry was used to verify RNF187 expression in tumor tissues. RNF187 expression was up-regulated in various cancers compared to that in normal tissues and associated with poor patient outcomes. Dysregulation of RNF187 expression in multiple cancer types was strongly correlated with DNA methylation, MMR, MSI, and TMB. RNF187 could interact with different immune cells in cancers. Biomarkers associated with RNF187 may be helpful for prognosis and immunology in treating pan-cancer patients.
癌症是全球死亡率最高的疾病。虽然存在挽救生命的筛查和治疗方法,但仍需要提高认识。RNF187是一种调节生物过程的E3连接酶,属于含RING结构域的E3连接酶家族。由于在肿瘤中异常表达,RNF187可能作为一种癌基因。然而,其与各种癌症的免疫浸润和预后的关系仍不清楚。我们检索了多个数据库,包括TCGA、GTE x、CCLE、TIMER和GSEA。使用R软件评估RNF187的差异表达、生存率、病理分期、DNA甲基化、肿瘤突变负荷(TMB)、微卫星不稳定性(MSI)、基因共表达分析、错配修复(MMR)、肿瘤微环境(TME)和免疫细胞浸润。收集临床病理数据,并使用免疫组织化学验证肿瘤组织中RNF187的表达。与正常组织相比,RNF187在各种癌症中的表达上调,且与患者预后不良相关。多种癌症类型中RNF187表达失调与DNA甲基化、MMR、MSI和TMB密切相关。RNF187可与癌症中的不同免疫细胞相互作用。与RNF187相关的生物标志物可能有助于泛癌患者的预后评估和免疫治疗。